SLC9A1 and ischemia: Since Na+ appears to enter during both ischemia and reperfusion, it is assumed that the optimal therapeutic strategy includes continuous Na+ channel blockers, an NHE1 inhibitor during ischemia, and an NHE1 inhibitor during reperfusion [57].